Business
PreveCeutical Announces Update to Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - April 2, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce a non-brokered private placement (the "Offering") of up to 16,666,667 units in the capital of the Company (the "Units") at a price of $0.03 per Unit for gross proceeds of up to $500,000. Each Unit consists of one (1) common share of the Company (each, a "Share") ...
About this update from Preveceutical Medical Inc
[{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - April 2, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce a non-brokered private placement (the "Offering") of up to 16,666,667 units in the capital of the Company (the "Units") at a price of $0.03 per Unit for gross proceeds of up to $500,000. Each Unit consists of one (1) common share of the Company (each, a "Share") and one-half (1/2) of one Share purchase warrant (each whole warrant, a "Warrant"). Each Warrant entitles the holder thereof to purchase an additional Share (each, a "Warrant Share") at an exercise price of $0.05 per Warrant Share for a period of 24 months from the closing of the Offering (the "Closing"); provided that the expiry of the Warrants can be accelerated if the closing price of the Company's common shares on the Canadian Securities Exchange (the "CSE") is $0.08 or greater for a minimum of ten consecutive trading days, and a notice of acceleration is provided in accordance with the terms of the Warrants. News issued on March 10, 2025, for the Private Placement has been increased to $500,000.","length":1255,"tagName":"p"},{"type":"text","content":"Finder's fees may be paid. The Company intends to use the aggregate gross proceeds from the sale of the Offering to pay outstanding payables, for operating expenses and for general working capital purposes.","length":210,"tagName":"p"},{"type":"text","content":"All securities issued in connection with the Offering will be subject to a statutory hold period expiring four months and one day after the Closing. Completion of the Offering remains subject to certain conditions, including, without limitation, confirmation of no objection from the CSE.","length":288,"tagName":"p"},{"type":"text","content":"About PreveCeutical","length":19,"tagName":"p"},{"type":"text","content":"PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesit...